Any thoughts or hopes?21 Sep 2008 20:41
ASM swung to a pretax profit of £13.4 million - year ended June 30.
[The company booked revenue of 39.5 million pounds compared with 8.0 million last time, below a range of six analysts' forecasts of between 42.68 million pounds and 45.00 million]
However, Chief Executive Glyn Edwards said: 'This has been a remarkable year. The progress of ASA404 in lung cancer and the acquisition of Xanthus have given our pipeline a new scale and maturity, with two drugs in Phase III and one in registration with the FDA. We are now well placed to make the transition from a drug development company into a company that both develops and commercialises.”
Still money to be made here???